The company has welcomed the recommendation but questioned the proposed pricing model, as it suggests cost neutrality compared to factor replacement therapy over 10 years. …
CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'
November 11, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Finalists named for the 2026 Patient's Choice awards
July 24, 2026 - - Latest News -
Australian company moving headquarters to US and restructuring workforce
July 24, 2026 - - Latest News -
The 'end of days' language is just a farcical attempt to shut down discussion
July 24, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News -
Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - - Latest News